# Sren M Bentzen

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 470 papers | 27,571 citations | 88 h-index | 150 g-index |
| 543 ext. papers | 31,333 ext. citations | 3.3 avg, IF | 7.03 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 470 | Use of normal tissue complication probability models in the clinic. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, S10-9 | 4 | 1027 |
| 469 | Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. *Radiotherapy and Oncology*, **2005**, 77, 18-24 | 5.3 | 777 |
| 468 | The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. *Lancet, The*, **2008**, 371, 1098-107 | 40 | 772 |
| 467 | Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. *Nature Reviews Cancer*, **2006**, 6, 702-13 | 31.3 | 709 |
| 466 | Radiation dose-volume effects in the lung. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, S70-6 | 4 | 704 |
| 465 | Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, S3-9 | 4 | 639 |
| 464 | Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. *Neuro-Oncology*, **2013**, 15, 1429-37 | 1 | 552 |
| 463 | Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. *Lancet, The*, **1995**, 345, 540-3 | 40 | 464 |
| 462 | Radiation oncology in the era of precision medicine. *Nature Reviews Cancer*, **2016**, 16, 234-49 | 31.3 | 438 |
| 461 | Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. *Lancet Oncology, The*, **2006**, 7, 467-71 | 21.7 | 410 |
| 460 | Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. *Radiotherapy and Oncology*, **2005**, 75, 9-17 | 5.3 | 367 |
| 459 | Time-dose factors in radiotherapy: a review of the human data. *Radiotherapy and Oncology*, **1990**, 19, 219-35 | 5.3 | 339 |
| 458 | Theragnostic imaging for radiation oncology: dose-painting by numbers. *Lancet Oncology, The*, **2005** , 6, 112-7 | 21.7 | 330 |
| 457 | Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. *International Journal of Radiation Oncology Biology Physics*, **2011**, 81, 59-68 | 4 | 305 |
| 456 | Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. *NMR in Biomedicine*, **2002**, 15, 132-42 | 4.4 | 297 |
| 455 | International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. *Radiotherapy and Oncology*, **2002**, 64, 275-80 | 5.3 | 257 |
| 454 | Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. *Journal of Clinical Oncology*, **2007**, 25, 1260-6 | 2.2 | 253 |

| | | | |
|---|---|---|---|
| 453 | Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. *Journal of Clinical Oncology* , **2006**, 24, 1057-63 | 2.2 | 252 |
| 452 | Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. *Journal of Clinical Oncology*, **2006**, 24, 727-35 | 2.2 | 244 |
| 451 | Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. *Radiotherapy and Oncology*, **1998**, 47, 233-40 | 5.3 | 243 |
| 450 | PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. *International Journal of Radiation Oncology Biology Physics*, **2007**, 68, 771-8 | 4 | 239 |
| 449 | Radiotherapy-related lung fibrosis enhanced by tamoxifen. *Journal of the National Cancer Institute*, **1996**, 88, 918-22 | 9.7 | 215 |
| 448 | Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. *Journal of Clinical Oncology*, **2005**, 23, 5560-7 | 2.2 | 213 |
| 447 | Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. *International Journal of Radiation Oncology Biology Physics*, **2008**, 71, 64-70 | 4 | 211 |
| 446 | Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. *Seminars in Radiation Oncology*, **2011**, 21, 101-10 | 5.5 | 197 |
| 445 | Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. *Journal of Clinical Oncology*, **2007**, 25, 4562-8 | 2.2 | 195 |
| 444 | Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. *Journal of Clinical Oncology*, **2010**, 28, 4912-8 | 2.2 | 191 |
| 443 | Clinical radiobiology of malignant melanoma. *Radiotherapy and Oncology*, **1989**, 16, 169-82 | 5.3 | 186 |
| 442 | Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. *International Journal of Hyperthermia*, **1996**, 12, 3-20 | 3.7 | 176 |
| 441 | Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. *International Journal of Radiation Oncology Biology Physics*, **2005**, 62, 988-94 | 4 | 173 |
| 440 | Latent-time estimation for late cutaneous and subcutaneous radiation reactions in a single-follow-up clinical study. *Radiotherapy and Oncology*, **1989**, 15, 267-74 | 5.3 | 171 |
| 439 | Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. *Radiotherapy and Oncology*, **2016**, 120, 441-446 | 5.3 | 171 |
| 438 | Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. *Radiotherapy and Oncology*, **2005**, 75, 355-65 | 5.3 | 170 |
| 437 | Patient-to-patient variability in the expression of radiation-induced normal tissue injury. *Seminars in Radiation Oncology*, **1994**, 4, 68-80 | 5.5 | 169 |
| 436 | Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. *Lancet Oncology, The*, **2012**, 13, 65-77 | 21.7 | 161 |

| | | | |
|---|---|---|---|
| 435 | Measurement of human tumour oxygenation status by a polarographic needle electrode. An analysis of inter- and intratumour heterogeneity. *Acta Oncologica*, **1994**, 33, 383-9 | 3.2 | 159 |
| 434 | Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. *International Journal of Radiation Oncology Biology Physics*, **2013**, 85, 74-80 | 4 | 156 |
| 433 | Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases boost: a planning study. *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, 589-97 | 4 | 153 |
| 432 | Relationship between early and late normal-tissue injury after postmastectomy radiotherapy. *Radiotherapy and Oncology*, **1991**, 20, 159-65 | 5.3 | 153 |
| 431 | The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, S155-60 | 4 | 148 |
| 430 | Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. *Journal of Clinical Oncology*, **1996**, 14, 1146-55 | 2.2 | 148 |
| 429 | Clinical radiobiology of squamous cell carcinoma of the oropharynx. *International Journal of Radiation Oncology Biology Physics*, **1991**, 20, 1197-206 | 4 | 146 |
| 428 | Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations. *International Journal of Radiation Oncology Biology Physics*, **2007**, 68, 1065-71 | 4 | 145 |
| 427 | Biologic basis for combining drugs with radiation. *Seminars in Radiation Oncology*, **2006**, 16, 2-9 | 5.5 | 145 |
| 426 | Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?. *International Journal of Radiation Oncology Biology Physics*, **2013**, 85, 89-94 | 4 | 144 |
| 425 | Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial. *Annals of Internal Medicine*, **2017**, 167, 311-318 | 8 | 142 |
| 424 | A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. *Acta Oncologica*, **2012**, 51, 975-83 | 3.2 | 142 |
| 423 | Bioeffect modeling and equieffective dose concepts in radiation oncology--terminology, quantities and units. *Radiotherapy and Oncology*, **2012**, 105, 266-8 | 5.3 | 138 |
| 422 | Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933. *Radiotherapy and Oncology*, **2010**, 95, 327-31 | 5.3 | 136 |
| 421 | Evaluation of early and late toxicities in chemoradiation trials. *Journal of Clinical Oncology*, **2007**, 25, 4096-103 | 2.2 | 135 |
| 420 | Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study. *International Journal of Radiation Oncology Biology Physics*, **2005**, 61, 649-55 | 4 | 135 |
| 419 | Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. *Radiotherapy and Oncology*, **2006**, 78, 236-44 | 5.3 | 134 |
| 418 | Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group. *Journal of Clinical Oncology*, **1997**, 15, 3030-7 | 2.2 | 133 |

| | | | |
|---|---|---|---|
| 417 | The predictive value of quantitative computed tomography for vertebral body compressive strength and ash density. *Bone*, **1989**, 10, 465-70 | 4.7 | 129 |
| 416 | Clinical evidence for tumor clonogen regeneration: interpretations of the data. *Radiotherapy and Oncology*, **1991**, 22, 161-6 | 5.3 | 129 |
| 415 | Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities. *International Journal of Radiation Oncology Biology Physics*, **2011**, 79, 1-9 | 4 | 123 |
| 414 | Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: work package 1. *Radiotherapy and Oncology*, **2005**, 75, 349-54 | 5.3 | 122 |
| 413 | The alpha/beta ratio for prostate cancer: what is it, really?. *Radiotherapy and Oncology*, **2005**, 76, 1-3 | 5.3 | 122 |
| 412 | Relationship between the in vitro radiosensitivity of skin fibroblasts and the expression of subcutaneous fibrosis, telangiectasia, and skin erythema after radiotherapy. *Radiotherapy and Oncology*, **1996**, 40, 101-9 | 5.3 | 122 |
| 411 | Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study. *Radiotherapy and Oncology*, **2005**, 77, 5-10 | 5.3 | 121 |
| 410 | The need for adverse effects reporting standards in oncology clinical trials. *Journal of Clinical Oncology*, **2004**, 22, 19-22 | 2.2 | 121 |
| 409 | Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. *Radiotherapy and Oncology*, **2001**, 60, 123-35 | 5.3 | 121 |
| 408 | Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. *International Journal of Radiation Oncology Biology Physics*, **2004**, 58, 1106-13 | 4 | 119 |
| 407 | Quantifying the position and steepness of radiation dose-response curves. *International Journal of Radiation Biology*, **1997**, 71, 531-42 | 2.9 | 114 |
| 406 | Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy. *International Journal of Radiation Oncology Biology Physics*, **2002**, 52, 198-204 | 4 | 113 |
| 405 | Towards evidence based radiation oncology: improving the design, analysis, and reporting of clinical outcome studies in radiotherapy. *Radiotherapy and Oncology*, **1998**, 46, 5-18 | 5.3 | 112 |
| 404 | Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. *Nature Clinical Practice Oncology*, **2007**, 4, 172-80 | | 111 |
| 403 | Integral radiation dose to normal structures with conformal external beam radiation. *International Journal of Radiation Oncology Biology Physics*, **2006**, 64, 962-7 | 4 | 110 |
| 402 | Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. *Journal of Clinical Oncology*, **2013**, 31, 4343-8 | 2.2 | 107 |
| 401 | Normal tissue effects: reporting and analysis. *Seminars in Radiation Oncology*, **2003**, 13, 189-202 | 5.5 | 107 |
| 400 | Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: individualized risk estimation. *Radiotherapy and Oncology*, **2002**, 65, 9-16 | 5.3 | 106 |

| | | | |
|---|---|---|---|
| 399 | The value of the NSD formula in equation of acute and late radiation complications in normal tissue following 2 and 5 fractions per week in breast cancer patients treated with postmastectomy irradiation. *Radiotherapy and Oncology*, **1987**, 9, 1-11 | 5.3 | 104 |
| 398 | A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. *Radiotherapy and Oncology*, **2014**, 111, 178-85 | 5.3 | 102 |
| 397 | Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. *Journal of Clinical Oncology*, **2001**, 19, 3376-84 | 2.2 | 102 |
| 396 | Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer. *Cancer Cell*, **2016**, 30, 637-650 | 24.3 | 102 |
| 395 | Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer. *Radiotherapy and Oncology*, **1999**, 53, 219-26 | 5.3 | 101 |
| 394 | Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. *Radiotherapy and Oncology*, **2016**, 118, 160-6 | 5.3 | 99 |
| 393 | Evidence for a positive correlation between in vitro radiosensitivity of normal human skin fibroblasts and the occurrence of subcutaneous fibrosis after radiotherapy. *International Journal of Radiation Biology*, **1994**, 66, 407-12 | 2.9 | 99 |
| 392 | Establishment of a Radiogenomics Consortium. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, 1295-6 | 4 | 98 |
| 391 | X-ray quantitative computed tomography: the relations to physical properties of proximal tibial trabecular bone specimens. *Journal of Biomechanics*, **1989**, 22, 837-44 | 2.9 | 98 |
| 390 | Early and late radiotherapeutic morbidity in 442 consecutive patients with locally advanced carcinoma of the uterine cervix. *International Journal of Radiation Oncology Biology Physics*, **1994**, 29, 941-52 | 4 | 96 |
| 389 | Fractionation parameters for human tissues and tumors. *International Journal of Radiation Biology*, **1989**, 56, 701-10 | 2.9 | 95 |
| 388 | Radiobiological considerations in the design of clinical trials. *Radiotherapy and Oncology*, **1994**, 32, 1-11 | 5.3 | 93 |
| 387 | Delay in the diagnosis of oral squamous cell carcinoma. *Clinical Otolaryngology*, **1995**, 20, 21-5 | 1.8 | 92 |
| 386 | Improving normal tissue complication probability models: the need to adopt a "data-pooling" culture. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, S151-4 | 4 | 90 |
| 385 | Time to loco-regional recurrence after resection of Dukes' B and C colorectal cancer with or without adjuvant postoperative radiotherapy. A multivariate regression analysis. *British Journal of Cancer*, **1992**, 65, 102-7 | 8.7 | 90 |
| 384 | Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. *Practical Radiation Oncology*, **2018**, 8, 354-360 | 2.8 | 90 |
| 383 | Clinical correlations between late normal tissue endpoints after radiotherapy: implications for predictive assays of radiosensitivity. *European Journal of Cancer*, **1993**, 29A, 1373-6 | 7.5 | 89 |
| 382 | Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. *Acta Oncologica*, **2005**, 44, 904-912 | 3.2 | 87 |

| | | | |
|---|---|---|---|
| 381 | Tumor volume and local control probability: clinical data and radiobiological interpretations. *International Journal of Radiation Oncology Biology Physics*, **1996**, 36, 247-51 | 4 | 87 |
| 380 | Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. *Journal of Clinical Oncology*, **2006**, 24, 45-51 | 2.2 | 85 |
| 379 | Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. *Radiotherapy and Oncology*, **2014**, 111, 360-5 | 5.3 | 84 |
| 378 | Fractionation sensitivity of a functional endpoint: impaired shoulder movement after post-mastectomy radiotherapy. *International Journal of Radiation Oncology Biology Physics*, **1989**, 17, 531-7 | 4 | 84 |
| 377 | Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. *Journal of Clinical Oncology*, **2000**, 18, 1733-9 | 2.2 | 83 |
| 376 | Major late toxicities after conformal radiotherapy for nasopharyngeal carcinoma-patient- and treatment-related risk factors. *International Journal of Radiation Oncology Biology Physics*, **2009**, 73, 1121-8 | 4 | 80 |
| 375 | Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation. *British Journal of Cancer*, **2002**, 86, 517-23 | 8.7 | 80 |
| 374 | Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. *Radiotherapy and Oncology*, **2012**, 105, 145-9 | 5.3 | 79 |
| 373 | Risk factors for central nervous system involvement in non-Hodgkins-lymphoma--a multivariate analysis. *Acta Oncologica*, **1996**, 35, 703-8 | 3.2 | 78 |
| 372 | Randomized controlled trials in health technology assessment: overkill or overdue?. *Radiotherapy and Oncology*, **2008**, 86, 142-7 | 5.3 | 77 |
| 371 | Morbidity related to axillary irradiation in the treatment of breast cancer. *Acta Oncologica*, **2000**, 39, 337-47 | 3.2 | 77 |
| 370 | Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology. *European Journal of Cancer*, **2003**, 39, 560-71 | 7.5 | 75 |
| 369 | Molecular therapy in head and neck oncology. *Nature Reviews Clinical Oncology*, **2009**, 6, 266-77 | 19.4 | 73 |
| 368 | Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. *Clinical Cancer Research*, **2004**, 10, 3745-54 | 12.9 | 72 |
| 367 | Direct estimation of latent time for radiation injury in late-responding normal tissues: gut, lung, and spinal cord. *International Journal of Radiation Biology*, **1989**, 55, 27-43 | 2.9 | 70 |
| 366 | Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. *Journal of Clinical Oncology*, **2018**, JCO1801097 | 2.2 | 70 |
| 365 | Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. *British Journal of Cancer*, **2019**, 120, 1003-1006 | 8.7 | 69 |
| 364 | Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. *Radiotherapy and Oncology*, **2016**, 121, 431-439 | 5.3 | 69 |

| | | | |
|---|---|---|---|
| 363 | An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: implications for radioresistance. *International Journal of Radiation Oncology Biology Physics*, **2006**, 65, 91-9 | 4 | 69 |
| 362 | Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia--a logistic regression analysis. *Acta Oncologica*, **1998**, 37, 277-84 | 3.2 | 69 |
| 361 | Why actuarial estimates should be used in reporting late normal-tissue effects of cancer treatment ... now!. *International Journal of Radiation Oncology Biology Physics*, **1995**, 32, 1531-4 | 4 | 69 |
| 360 | Prognostic factors in osteosarcomas. A regression analysis. *Cancer*, **1988**, 62, 194-202 | 6.4 | 68 |
| 359 | Severe late toxicities following concomitant chemoradiotherapy compared to radiotherapy alone in cervical cancer: an inter-era analysis. *International Journal of Radiation Oncology Biology Physics*, **2012**, 84, 973-82 | 4 | 66 |
| 358 | Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study. *Physics in Medicine and Biology*, **2007**, 52, 499-513 | 3.8 | 66 |
| 357 | Potential clinical impact of normal-tissue intrinsic radiosensitivity testing. *Radiotherapy and Oncology*, **1997**, 43, 121-31 | 5.3 | 65 |
| 356 | Radiotherapy adapted to spatial and temporal variability in tumor hypoxia. *International Journal of Radiation Oncology Biology Physics*, **2007**, 68, 1496-504 | 4 | 65 |
| 355 | Early and late normal-tissue injury after postmastectomy radiotherapy alone or combined with chemotherapy. *International Journal of Radiation Biology*, **1989**, 56, 711-5 | 2.9 | 65 |
| 354 | Mechanical strength of tibial trabecular bone evaluated by X-ray computed tomography. *Journal of Biomechanics*, **1987**, 20, 743-52 | 2.9 | 64 |
| 353 | "Radiobiology of Proton Therapy": Results of an international expert workshop. *Radiotherapy and Oncology*, **2018**, 128, 56-67 | 5.3 | 64 |
| 352 | Randomized trial of hyperfractionation versus conventional fractionation in T2 squamous cell carcinoma of the vocal cord (RTOG 9512). *International Journal of Radiation Oncology Biology Physics*, **2014**, 89, 958-963 | 4 | 61 |
| 351 | Risk factors for radiation-induced hypothyroidism: a literature-based meta-analysis. *Cancer*, **2011**, 117, 5250-60 | 6.4 | 61 |
| 350 | Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial. *International Journal of Radiation Oncology Biology Physics*, **2008**, 71, 1103-10 | 4 | 61 |
| 349 | Some methodological problems in estimating radiobiological parameters from clinical data. Alpha/beta ratios and electron RBE for cutaneous reactions in patients treated with postmastectomy radiotherapy. *Acta Oncologica*, **1988**, 27, 105-16 | 3.2 | 61 |
| 348 | Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. *Physics in Medicine and Biology*, **2008**, 53, 4153-67 | 3.8 | 59 |
| 347 | High-tech in radiation oncology: should there be a ceiling?. *International Journal of Radiation Oncology Biology Physics*, **2004**, 58, 320-30 | 4 | 59 |
| 346 | National audit of the management and outcome of carcinoma of the cervix treated with radiotherapy in 1993. *Clinical Oncology*, **2000**, 12, 347-53 | 2.8 | 59 |

| | | | |
|---|---|---|---|
| 345 | Are we influencing outcome in oropharynx cancer with intensity-modulated radiotherapy? An inter-era comparison. *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, 1032-41 | 4 | 57 |
| 344 | Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck: clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy. *Radiotherapy and Oncology*, **1996**, 38, 89-101 | 5.3 | 57 |
| 343 | Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy. *Oncologist*, **2017**, 22, 737-742 | 5.7 | 56 |
| 342 | Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, S145-50 | 4 | 55 |
| 341 | Fractionation sensitivity and latency of telangiectasia after postmastectomy radiotherapy: a graded-response analysis. *Radiotherapy and Oncology*, **1990**, 18, 95-106 | 5.3 | 55 |
| 340 | Radiogenomics: the search for genetic predictors of radiotherapy response. *Future Oncology*, **2014**, 10, 2391-406 | 3.6 | 54 |
| 339 | Estimated clinical benefit of protecting neurogenesis in the developing brain during radiation therapy for pediatric medulloblastoma. *Neuro-Oncology*, **2012**, 14, 882-9 | 1 | 53 |
| 338 | Steepness of the clinical dose-control curve and variation in the in vitro radiosensitivity of head and neck squamous cell carcinoma. *International Journal of Radiation Biology*, **1992**, 61, 417-23 | 2.9 | 53 |
| 337 | Cancer risk from bone morphogenetic protein exposure in spinal arthrodesis. *Journal of Bone and Joint Surgery - Series A*, **2014**, 96, 1417-22 | 5.6 | 52 |
| 336 | Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. *Radiotherapy and Oncology*, **2012**, 105, 289-95 | 5.3 | 52 |
| 335 | Repopulation in radiation oncology: perspectives of clinical research. *International Journal of Radiation Biology*, **2003**, 79, 581-5 | 2.9 | 52 |
| 334 | Clinical impact of dosimetry quality assurance programmes assessed by radiobiological modelling of data from the thermoluminescent dosimetry study of the European Organization for Research and Treatment of Cancer. *European Journal of Cancer*, **2000**, 36, 615-20 | 7.5 | 52 |
| 333 | Modern hypofractionation schedules for tangential whole breast irradiation decrease the fraction size-corrected dose to the heart. *Clinical Oncology*, **2013**, 25, 147-52 | 2.8 | 51 |
| 332 | Life years lost--comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale. *Cancer*, **2012**, 118, 5432-40 | 6.4 | 51 |
| 331 | Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG). *British Journal of Haematology*, **1997**, 96, 103-10 | 4.5 | 51 |
| 330 | Dose escalated, hypofractionated radiotherapy using helical tomotherapy for inoperable non-small cell lung cancer: preliminary results of a risk-stratified phase I dose escalation study. *Technology in Cancer Research and Treatment*, **2008**, 7, 441-7 | 2.7 | 51 |
| 329 | Histopathologic, stereologic, epidemiologic, and clinical parameters in the prognostic evaluation of squamous cell carcinoma of the oral cavity. *Head and Neck*, **1996**, 18, 142-52 | 4.2 | 51 |
| 328 | Establishing Evidence-Based Indications for Proton Therapy: An Overview of Current Clinical Trials. *International Journal of Radiation Oncology Biology Physics*, **2017**, 97, 228-235 | 4 | 50 |

| | | | |
|---|---|---|---|
| 327 | Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. *International Journal of Radiation Oncology Biology Physics*, **2012**, 83, 782-90 | 4 | 50 |
| 326 | Influence of connective tissue diseases on the expression of radiation side effects: a systematic review. *Radiotherapy and Oncology*, **2006**, 78, 123-30 | 5.3 | 50 |
| 325 | Relationship between DNA double-strand breaks, cell killing, and fibrosis studied in confluent skin fibroblasts derived from breast cancer patients. *International Journal of Radiation Oncology Biology Physics*, **2000**, 46, 481-90 | 4 | 50 |
| 324 | Use of tumour markers in monitoring the course of ovarian cancer. *Annals of Oncology*, **1999**, 10 Suppl 1, 21-7 | 10.3 | 50 |
| 323 | Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. *EBioMedicine*, **2016**, 10, 150-63 | 8.8 | 50 |
| 322 | Single institution experience treating 104 vestibular schwannomas with fractionated stereotactic radiation therapy or stereotactic radiosurgery. *Journal of Neuro-Oncology*, **2014**, 116, 187-93 | 4.8 | 49 |
| 321 | Standardized Total Average Toxicity score: a scale- and grade-independent measure of late radiotherapy toxicity to facilitate pooling of data from different studies. *International Journal of Radiation Oncology Biology Physics*, **2012**, 82, 1065-74 | 4 | 49 |
| 320 | NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. *Journal of the National Cancer Institute*, **2013**, 105, 11-24 | 9.7 | 49 |
| 319 | Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience. *Head and Neck*, **2010**, 32, 599-606 | 4.2 | 49 |
| 318 | An evolutionary-game model of tumour-cell interactions: possible relevance to gene therapy. *European Journal of Cancer*, **2001**, 37, 2116-20 | 7.5 | 49 |
| 317 | Locoregional control of non-small cell lung cancer in relation to automated early assessment of tumor regression on cone beam computed tomography. *International Journal of Radiation Oncology Biology Physics*, **2014**, 89, 916-23 | 4 | 48 |
| 316 | Towards individualized dose constraints: Adjusting the QUANTEC radiation pneumonitis model for clinical risk factors. *Acta Oncologica*, **2014**, 53, 605-12 | 3.2 | 48 |
| 315 | On the sensitivity of IMRT dose optimization to the mathematical form of a biological imaging-based prescription function. *Physics in Medicine and Biology*, **2009**, 54, 1483-501 | 3.8 | 48 |
| 314 | Quantitative clinical radiobiology. *Acta Oncologica*, **1993**, 32, 259-75 | 3.2 | 48 |
| 313 | A regression analysis of prognostic factors after resection of Dukes' B and C carcinoma of the rectum and rectosigmoid. Does post-operative radiotherapy change the prognosis?. *British Journal of Cancer*, **1988**, 58, 195-201 | 8.7 | 48 |
| 312 | STROGAR - STrengthening the Reporting Of Genetic Association studies in Radiogenomics. *Radiotherapy and Oncology*, **2014**, 110, 182-8 | 5.3 | 47 |
| 311 | Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix. *International Journal of Radiation Oncology Biology Physics*, **1989**, 16, 1069-72 | 4 | 47 |
| 310 | Assessment of Machine Learning vs Standard Prediction Rules for Predicting Hospital Readmissions. *JAMA Network Open*, **2019**, 2, e190348 | 10.4 | 46 |

| | | | |
|---|---|---|---|
| 309 | Dose Response and Fractionation Sensitivity of Prostate Cancer After External Beam Radiation Therapy: A Meta-analysis of Randomized Trials. *International Journal of Radiation Oncology Biology Physics*, **2018**, 100, 858-865 | 4 | 46 |
| 308 | From CHART to CHARTWEL in non-small cell lung cancer: clinical radiobiological modelling of the expected change in outcome. *Clinical Oncology*, **2002**, 14, 372-81 | 2.8 | 46 |
| 307 | Differentiation state of skin fibroblast cultures versus risk of subcutaneous fibrosis after radiotherapy. *Radiotherapy and Oncology*, **1998**, 47, 263-9 | 5.3 | 46 |
| 306 | Prognostic value of pretreatment factors in patients with locally advanced carcinoma of the uterine cervix treated by radiotherapy alone. *Acta Oncologica*, **1995**, 34, 787-95 | 3.2 | 46 |
| 305 | Doubly Excited States in Be III. *Physica Scripta*, **1980**, 22, 119-122 | 2.6 | 46 |
| 304 | Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling. *Nuclear Medicine and Biology*, **2011**, 38, 771-80 | 2.1 | 44 |
| 303 | Does variation in the in vitro cellular radiosensitivity explain the shallow clinical dose-control curve for malignant melanoma?. *International Journal of Radiation Biology*, **1990**, 57, 117-26 | 2.9 | 44 |
| 302 | Hypothyroidism after primary radiotherapy for head and neck squamous cell carcinoma: normal tissue complication probability modeling with latent time correction. *Radiotherapy and Oncology*, **2013**, 109, 317-22 | 5.3 | 43 |
| 301 | Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer. *International Journal of Radiation Oncology Biology Physics*, **2012**, 82, 184-90 | 4 | 43 |
| 300 | bcl-2 expression in head and neck cancer: an enigmatic prognostic marker. *International Journal of Radiation Oncology Biology Physics*, **2001**, 49, 435-41 | 4 | 42 |
| 299 | Evaluation of the spatial resolution of a CT scanner by direct analysis of the edge response function. *Medical Physics*, **1983**, 10, 579-81 | 4.4 | 42 |
| 298 | Tumor cell proliferation and survival in patients with prostate cancer followed expectantly. *Journal of Urology*, **1998**, 159, 1609-14 | 2.5 | 41 |
| 297 | Compliance to the prescribed dose and overall treatment time in five randomized clinical trials of altered fractionation in radiotherapy for head-and-neck carcinomas. *International Journal of Radiation Oncology Biology Physics*, **2003**, 55, 568-75 | 4 | 41 |
| 296 | Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC). *Lung Cancer*, **2017**, 104, 52-57 | 5.9 | 40 |
| 295 | Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. *Acta Oncologica*, **2005**, 44, 904-12 | 3.2 | 40 |
| 294 | Rates of local control, metastasis, and overall survival in patients with posterior uveal melanomas treated with ruthenium-106 plaques. *Radiotherapy and Oncology*, **1993**, 28, 148-56 | 5.3 | 40 |
| 293 | Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer. *Radiotherapy and Oncology*, **2016**, 120, 76-80 | 5.3 | 40 |
| 292 | Carcinoma of the cervix and the use of hyperbaric oxygen with radiotherapy: a report of a randomised controlled trial. *Radiotherapy and Oncology*, **1999**, 53, 93-8 | 5.3 | 39 |

| | | | |
|---|---|---|---|
| 291 | A re-analysis of available dose-response and time-dose data in Hodgkin's disease. *Radiotherapy and Oncology*, **1994**, 30, 227-30 | 5.3 | 39 |
| 290 | The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists. *International Journal of Radiation Oncology Biology Physics*, **2019**, 105, 698-712 | 4 | 38 |
| 289 | Randomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: results of RTOG 0215. *Journal of Sexual Medicine*, **2011**, 8, 1228-38 | 1.1 | 38 |
| 288 | Feasibility of dose painting using volumetric modulated arc optimization and delivery. *Acta Oncologica*, **2010**, 49, 964-71 | 3.2 | 38 |
| 287 | Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. 1996. *International Journal of Hyperthermia*, **2009**, 25, 323-34 | 3.7 | 38 |
| 286 | Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis. *British Journal of Cancer*, **1998**, 78, 96-9 | 8.7 | 38 |
| 285 | From cellular to high-throughput predictive assays in radiation oncology: challenges and opportunities. *Seminars in Radiation Oncology*, **2008**, 18, 75-88 | 5.5 | 38 |
| 284 | Radiation dose response of normal lung assessed by Cone Beam CT - a potential tool for biologically adaptive radiation therapy. *Radiotherapy and Oncology*, **2011**, 100, 351-5 | 5.3 | 37 |
| 283 | Maximal neutropenia during chemotherapy and radiotherapy is significantly associated with the development of acute radiation-induced dysphagia in lung cancer patients. *Annals of Oncology*, **2007**, 18, 909-16 | 10.3 | 37 |
| 282 | Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas. *Radiotherapy and Oncology*, **2004**, 72, 275-82 | 5.3 | 36 |
| 281 | A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer. *International Journal of Radiation Oncology Biology Physics*, **2010**, 77, 1066-71 | 4 | 35 |
| 280 | Early morbidity after radiotherapy with or without chemotherapy in advanced head and neck cancer. Experience from four nonrandomized studies. *Strahlentherapie Und Onkologie*, **2003**, 179, 390-5 | 4.3 | 35 |
| 279 | Pediatric Normal Tissue Effects in the Clinic (PENTEC): An International Collaboration to Analyse Normal Tissue Radiation Dose-Volume Response Relationships for Paediatric Cancer Patients. *Clinical Oncology*, **2019**, 31, 199-207 | 2.8 | 34 |
| 278 | Understanding High-Dose, Ultra-High Dose Rate, and Spatially Fractionated Radiation Therapy. *International Journal of Radiation Oncology Biology Physics*, **2020**, 107, 766-778 | 4 | 34 |
| 277 | Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost. *International Journal of Radiation Oncology Biology Physics*, **2014**, 90, 110-8 | 4 | 34 |
| 276 | Prognostic factors in papillary and follicular thyroid carcinomas: p53 expression is a significant indicator of prognosis. *Laryngoscope*, **1998**, 108, 243-9 | 3.6 | 34 |
| 275 | Linear accelerator radiosurgery for trigeminal neuralgia. *Neurosurgery*, **2005**, 57, 1193-200; discussion 1193-200 | 3.2 | 34 |
| 274 | Hyperfractionated radiotherapy in head and neck cancer: a second look at the clinical data. *Radiotherapy and Oncology*, **1998**, 46, 127-30 | 5.3 | 34 |

| | | | |
|---|---|---|---|
| 273 | Carbogen and nicotinamide in locally advanced bladder cancer: early results of a phase-III randomized trial. *Radiotherapy and Oncology*, **2009**, 91, 120-5 | 5.3 | 33 |
| 272 | HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer. *International Journal of Radiation Oncology Biology Physics*, **2008**, 71, 132-8 | 4 | 33 |
| 271 | Fibroblast differentiation in subcutaneous fibrosis after postmastectomy radiotherapy. *Acta Oncologica*, **2000**, 39, 383-8 | 3.2 | 33 |
| 270 | Short and long term outcome in a consecutive series of 419 patients with acute dialysis-requiring renal failure. *Scandinavian Journal of Urology and Nephrology*, **1993**, 27, 453-62 | | 33 |
| 269 | Assessment of morbidity in carcinoma of the cervix: a comparison of the LENT SOMA scales and the Franco-Italian glossary. *Radiotherapy and Oncology*, **2003**, 69, 195-200 | 5.3 | 32 |
| 268 | Time course of radiological lung density changes after postmastectomy radiotherapy. *Acta Oncologica*, **2000**, 39, 181-7 | 3.2 | 32 |
| 267 | Density changes at the proximal tibia after medial meniscectomy. *Journal of Orthopaedic Research*, **1989**, 7, 744-53 | 3.8 | 32 |
| 266 | Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. *Journal of the National Cancer Institute*, **2020**, 112, 179-190 | 9.7 | 32 |
| 265 | On the use of hyperpolarized helium MRI for conformal avoidance lung radiotherapy. *Medical Dosimetry*, **2010**, 35, 297-303 | 1.3 | 31 |
| 264 | Time evolution of regional CT density changes in normal lung after IMRT for NSCLC. *Radiotherapy and Oncology*, **2013**, 109, 89-94 | 5.3 | 30 |
| 263 | Interactive decision-support tool for risk-based radiation therapy plan comparison for Hodgkin lymphoma. *International Journal of Radiation Oncology Biology Physics*, **2014**, 88, 433-45 | 4 | 30 |
| 262 | Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria. *Aids*, **2017**, 31, 857-862 | 3.5 | 29 |
| 261 | The impact of hybrid PET-CT scan on overall oncologic management, with a focus on radiotherapy planning: a prospective, blinded study. *Technology in Cancer Research and Treatment*, **2009**, 8, 149-58 | 2.7 | 29 |
| 260 | A modelling study of the potential influence of low dose hypersensitivity on radiation treatment planning. *Radiotherapy and Oncology*, **2006**, 79, 115-21 | 5.3 | 29 |
| 259 | Investigation of relationship between change in locoregional control and change in overall survival in randomized controlled trials of modified radiotherapy in head-and-neck cancer. *International Journal of Radiation Oncology Biology Physics*, **2004**, 60, 1405-9 | 4 | 29 |
| 258 | Reporting radiotherapeutic complications in patients with uterine cervical cancer. The importance of latency and classification system. *Radiotherapy and Oncology*, **1993**, 28, 134-41 | 5.3 | 29 |
| 257 | Blood transfusion and prognosis in Dukes' B and C colorectal cancer. *European Journal of Cancer & Clinical Oncology*, **1990**, 26, 457-63 | | 29 |
| 256 | Spectroscopy of the uranium ion using collinear fast-beam-low-dye-laser modulation spectroscopy. Transition energies and excited-state lifetimes. *Physical Review A*, **1981**, 24, 2523-2531 | 2.6 | 29 |

| | | | |
|---|---|---|---|
| 255 | Joint Estimation of Cardiac Toxicity and Recurrence Risks After Comprehensive Nodal Photon Versus Proton Therapy for Breast Cancer. *International Journal of Radiation Oncology Biology Physics*, **2017**, 97, 754-761 | 4 | 28 |
| 254 | Quantification of Acute Skin Toxicities in Patients With Breast Cancer Undergoing Adjuvant Proton versus Photon Radiation Therapy: A Single Institutional Experience. *International Journal of Radiation Oncology Biology Physics*, **2019**, 104, 1084-1090 | 4 | 28 |
| 253 | Hippocampal sparing radiotherapy for pediatric medulloblastoma: impact of treatment margins and treatment technique. *Neuro-Oncology*, **2014**, 16, 594-602 | 1 | 28 |
| 252 | Hypofractionated radiotherapy for breast cancer. *New England Journal of Medicine*, **2010**, 362, 1843; author reply 1843-4 | 59.2 | 28 |
| 251 | Clinical radiation doses for spinal cord: the 1998 international questionnaire. *Radiotherapy and Oncology*, **2000**, 55, 295-300 | 5.3 | 28 |
| 250 | Lack of predictive value of potential doubling time and iododeoxyuridine labelling index in radiotherapy of squamous cell carcinoma of the head and neck. *Radiotherapy and Oncology*, **1998**, 46, 147-55 | 5.3 | 28 |
| 249 | Loss of reirradiation tolerance in the kidney with increasing time after single or fractionated partial tolerance doses. *International Journal of Radiation Biology*, **1994**, 66, 169-79 | 2.9 | 28 |
| 248 | Dose painting and theragnostic imaging: towards the prescription, planning and delivery of biologically targeted dose distributions in external beam radiation oncology. *Cancer Treatment and Research*, **2008**, 139, 41-62 | 3.5 | 28 |
| 247 | PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma. *Cancer Immunology, Immunotherapy*, **2018**, 67, 805-814 | 7.4 | 27 |
| 246 | Methods for estimating the site of origin of locoregional recurrence in head and neck squamous cell carcinoma. *Strahlentherapie Und Onkologie*, **2012**, 188, 671-6 | 4.3 | 27 |
| 245 | Prognostic factor studies in oncology: osteosarcoma as a clinical example. *International Journal of Radiation Oncology Biology Physics*, **2001**, 49, 513-8 | 4 | 27 |
| 244 | New options in direct analysis of dose-response data. *International Journal of Radiation Biology*, **1990**, 57, 221-5 | 2.9 | 27 |
| 243 | Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: An analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation. *Radiotherapy and Oncology*, **2016**, 121, 420-423 | 5.3 | 27 |
| 242 | Radiotherapy for breast cancer, the TARGIT-A trial. *Lancet, The*, **2014**, 383, 1716-7 | 40 | 26 |
| 241 | Study design and rationale for ELPIS: A phase I/IIb randomized pilot study of allogeneic human mesenchymal stem cell injection in patients with hypoplastic left heart syndrome. *American Heart Journal*, **2017**, 192, 48-56 | 4.9 | 26 |
| 240 | Conducting radiogenomic research--do not forget careful consideration of the clinical data. *Radiotherapy and Oncology*, **2012**, 105, 337-40 | 5.3 | 26 |
| 239 | The translational research chain: is it delivering the goods?. *International Journal of Radiation Oncology Biology Physics*, **2001**, 49, 345-51 | 4 | 26 |
| 238 | Remodeling of the tibial plateau after knee replacement. CT bone densitometry. *Acta Orthopaedica* , **1988**, 59, 567-73 | | 26 |

| | | | |
|---|---|---|---|
| 237 | Relationship between radioligand binding assay, immunoenzyme assay and immunohistochemical assay for estrogen receptors in human breast cancer and association with tumor differentiation. *European Journal of Cancer & Clinical Oncology*, **1988**, 24, 377-84 | | 26 |
| 236 | Doubly excited quartet states in Be II. *Journal of Physics B: Atomic and Molecular Physics*, **1981**, 14, 3435-3443 | | 26 |
| 235 | Immunohistochemical biomarkers and FDG uptake on PET/CT in head and neck squamous cell carcinoma. *Acta Oncologica*, **2015**, 54, 1408-15 | 3.2 | 24 |
| 234 | Risk of cerebrovascular events in elderly patients after radiation therapy versus surgery for early-stage glottic cancer. *International Journal of Radiation Oncology Biology Physics*, **2013**, 87, 290-6 | 4 | 24 |
| 233 | Intensity-modulated radiotherapy might increase pneumonitis risk relative to three-dimensional conformal radiotherapy in patients receiving combined chemotherapy and radiotherapy: a modeling study of dose dumping. *International Journal of Radiation Oncology Biology Physics*, **2011**, 80, 893-9 | 4 | 24 |
| 232 | Failure-probability driven dose painting. *Medical Physics*, **2013**, 40, 081717 | 4.4 | 23 |
| 231 | Hypofractionation does not increase radiation pneumonitis risk with modern conformal radiation delivery techniques. *Acta Oncologica*, **2010**, 49, 1052-7 | 3.2 | 23 |
| 230 | Increasing toxicity in nonoperative head and neck cancer treatment: investigations and interventions. *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, S79-82 | 4 | 23 |
| 229 | Multiple biomarker tissue microarrays: bioinformatics and practical approaches. *Cancer and Metastasis Reviews*, **2008**, 27, 481-94 | 9.6 | 23 |
| 228 | Late functional response of mouse urinary bladder to fractionated X-irradiation. *International Journal of Radiation Biology*, **1999**, 75, 1307-15 | 2.9 | 23 |
| 227 | Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era. *Frontiers in Oncology*, **2017**, 7, 83 | 5.3 | 22 |
| 226 | Radiation Fractionation Schedules Published During the COVID-19 Pandemic: A Systematic Review of the Quality of Evidence and Recommendations for Future Development. *International Journal of Radiation Oncology Biology Physics*, **2020**, 108, 379-389 | 4 | 22 |
| 225 | NK cell expression of Tim-3: First impressions matter. *Immunobiology*, **2019**, 224, 362-370 | 3.4 | 21 |
| 224 | Gaucher Disease-Induced Pluripotent Stem Cells Display Decreased Erythroid Potential and Aberrant Myelopoiesis. *Stem Cells Translational Medicine*, **2015**, 4, 878-86 | 6.9 | 21 |
| 223 | Estimated radiation pneumonitis risk after photon versus proton therapy alone or combined with chemotherapy for lung cancer. *Acta Oncologica*, **2011**, 50, 772-6 | 3.2 | 21 |
| 222 | Overall treatment time and tumor control dose for head and neck tumors: the dog leg revisited. *Radiotherapy and Oncology*, **1992**, 25, 143-4 | 5.3 | 21 |
| 221 | Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014. *Clinical Pharmacology and Therapeutics*, **2018**, 104, 390-400 | 6.1 | 20 |
| 220 | Molecular imaging biomarkers of resistance to radiation therapy for spontaneous nasal tumors in canines. *International Journal of Radiation Oncology Biology Physics*, **2015**, 91, 787-95 | 4 | 19 |

| | | | |
|---|---|---|---|
| 219 | Radiosensitivity of normal fibroblasts from breast cancer patients assessed by the micronucleus and colony assays. *International Journal of Radiation Biology*, **1998**, 73, 671-8 | 2.9 | 19 |
| 218 | Molecular biomarkers and site of first recurrence after radiotherapy for head and neck cancer. *European Journal of Cancer*, **2004**, 40, 2734-41 | 7.5 | 19 |
| 217 | UPDATED DATA FOR CHART IN NSCLC: FURTHER ANALYSES. *Radiotherapy and Oncology*, **2000**, 55, 86-87 | 5.3 | 19 |
| 216 | Modelling of serial carcinoembryonic antigen changes in colorectal cancer. *Scandinavian Journal of Clinical and Laboratory Investigation*, **1993**, 53, 751-5 | 2 | 19 |
| 215 | Dose-response of acute urinary toxicity of long-course preoperative chemoradiotherapy for rectal cancer. *Acta Oncologica*, **2015**, 54, 179-86 | 3.2 | 18 |
| 214 | Global and Regional Myocardial Innervation Before and After Ablation of Drug-Refractory Ventricular Tachycardia Assessed with 123I-MIBG. *Journal of Nuclear Medicine*, **2015**, 56 Suppl 4, 52S-58S | 8.9 | 18 |
| 213 | Steepness of the dose-response curve as a function of volume in an experimental tumor irradiated under ambient or hypoxic conditions. *International Journal of Radiation Oncology Biology Physics*, **1997**, 39, 797-802 | 4 | 18 |
| 212 | Selective assessment of in vitro radiosensitivity of tumour cells and fibroblasts from single tumour biopsies using immunocytochemical identification of colonies in the soft agar clonogenic assay. *Radiotherapy and Oncology*, **1995**, 37, 87-99 | 5.3 | 18 |
| 211 | Experimental investigation of doubly excited states in Be II. *Physical Review A*, **1982**, 26, 2639-2642 | 2.6 | 18 |
| 210 | Factors Influencing Management and Outcome in Patients with Occult Breast Cancer with Axillary Lymph Node Involvement: Analysis of the National Cancer Database. *Annals of Surgical Oncology*, **2017**, 24, 2907-2914 | 3.1 | 17 |
| 209 | Prognostic value of 18F-fludeoxyglucose uptake in 287 patients with head and neck squamous cell carcinoma. *Head and Neck*, **2015**, 37, 1274-81 | 4.2 | 17 |
| 208 | Fractionation sensitivity and latency of late radiation injury to the mouse urinary bladder. *Radiotherapy and Oncology*, **1992**, 25, 301-7 | 5.3 | 17 |
| 207 | New identifications of doubly excited quartet states in Be II. *Journal of Physics B: Atomic and Molecular Physics*, **1982**, 15, L71-L74 | | 17 |
| 206 | Lifetime measurements in singly ionized erbium using fast-beam laser-modulation spectroscopy. *Journal of the Optical Society of America*, **1982**, 72, 1210 | | 17 |
| 205 | Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. *Neuro-Oncology*, **2021**, 23, 112-121 | 1 | 17 |
| 204 | External validation of a normal tissue complication probability model for radiation-induced hypothyroidism in an independent cohort. *Acta Oncologica*, **2015**, 54, 1301-9 | 3.2 | 16 |
| 203 | Diminishing Returns From Ultrahypofractionated Radiation Therapy for Prostate Cancer. *International Journal of Radiation Oncology Biology Physics*, **2020**, 107, 299-304 | 4 | 16 |
| 202 | Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation. *Journal of Neuro-Oncology*, **2017**, 134, 331-338 | 4.8 | 16 |

| | | | |
|---|---|---|---|
| 201 | Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET from post-treatment FDG PET: an exploratory study. *Radiotherapy and Oncology*, **2012**, 105, 41-8 | 5.3 | 16 |
| 200 | A systematic methodology review of phase I radiation dose escalation trials. *Radiotherapy and Oncology*, **2010**, 95, 135-41 | 5.3 | 16 |
| 199 | Plasma tetranectin and colorectal cancer. *European Journal of Cancer*, **1995**, 31A, 888-94 | 7.5 | 16 |
| 198 | Cytotoxic effect of misonidazole and cyclophosphamide on aerobic and hypoxic cells in a C3H mammary carcinoma in vivo. *British Journal of Cancer*, **1990**, 61, 61-4 | 8.7 | 16 |
| 197 | Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia. *Cancer Chemotherapy and Pharmacology*, **2018**, 81, 217-222 | 3.5 | 16 |
| 196 | The effect of hypoxia and hyperoxia on nucleoside triphosphate/inorganic phosphate, pO2 and radiation response in an experimental tumour model. *British Journal of Cancer*, **1997**, 76, 1432-9 | 8.7 | 15 |
| 195 | Increased Oral Mucositis after IMRT versus Non-IMRT when Combined with Cetuximab and Cisplatin or Docetaxel for Head and Neck Cancer: Preliminary Results of RTOG 0234. *International Journal of Radiation Oncology Biology Physics*, **2008**, 72, S33 | 4 | 15 |
| 194 | Pre-treatment proliferation and the outcome of conventional and accelerated radiotherapy. *European Journal of Cancer*, **2006**, 42, 363-71 | 7.5 | 15 |
| 193 | Radiotherapy for head and neck cancer: latest developments and future perspectives. *Current Opinion in Oncology*, **2006**, 18, 240-6 | 4.2 | 15 |
| 192 | Fractionated radiotherapy for metastatic bone pain: evidence-based medicine or...?. *International Journal of Radiation Oncology Biology Physics*, **2000**, 46, 681-3 | 4 | 15 |
| 191 | Incidence and latency of radiation reactions. *Radiotherapy and Oncology*, **1989**, 14, 261-2 | 5.3 | 15 |
| 190 | Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma?. *International Journal of Radiation Oncology Biology Physics*, **2021**, 110, 172-187 | 4 | 15 |
| 189 | Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database. *Oral Oncology*, **2018**, 86, 132-140 | 4.4 | 15 |
| 188 | Recombinant human IgG1 based Fc multimers, with limited FcR binding capacity, can effectively inhibit complement-mediated disease. *Journal of Autoimmunity*, **2017**, 84, 97-108 | 15.5 | 14 |
| 187 | Optimizing the radiation therapy dose prescription for pediatric medulloblastoma: minimizing the life years lost attributable to failure to control the disease and late complication risk. *Acta Oncologica*, **2014**, 53, 462-70 | 3.2 | 14 |
| 186 | Locoregional recurrence following accelerated partial breast irradiation for early-stage invasive breast cancer: significance of estrogen receptor status and other pathological variables. *Annals of Surgical Oncology*, **2013**, 20, 3446-52 | 3.1 | 14 |
| 185 | Repopulation in the SCCVII squamous cell carcinoma assessed by an in vivo-in vitro excision assay. *Radiotherapy and Oncology*, **1996**, 39, 137-44 | 5.3 | 14 |
| 184 | Direct estimation of the fraction of hypoxic cells from tumour--control data obtained under aerobic and clamped conditions. *International Journal of Radiation Biology*, **1991**, 59, 1435-40 | 2.9 | 14 |

| | | | |
|---|---|---|---|
| 183 | Problems related to lifetime measurements in complex atoms using beam-foil and fast-beam/laser spectroscopy. *Nuclear Instruments & Methods in Physics Research*, **1982**, 202, 139-145 | | 14 |
| 182 | Elevation of prostaglandin E2 in lung cancer patients with digital clubbing. *Journal of Thoracic Oncology*, **2012**, 7, 1877-1878 | 8.9 | 13 |
| 181 | Steepness of the radiation dose-response curve for dose-per-fraction escalation keeping the number of fractions fixed. *Acta Oncologica*, **2005**, 44, 825-8 | 3.2 | 13 |
| 180 | How useful are observational reports in the evaluation of interventions for radiation morbidity?: an analysis of formalin therapy for late radiation proctitis. *Radiotherapy and Oncology*, **2002**, 64, 291-5 | 5.3 | 13 |
| 179 | Late morbidity: the Damocles Sword of radiotherapy?. *Radiotherapy and Oncology*, **2001**, 61, 219-21 | 5.3 | 13 |
| 178 | Influence of sampling time on assessment of potential doubling time. *Cytometry*, **1994**, 16, 144-51 | | 13 |
| 177 | Spatio-temporal stability of pre-treatment 18F-Fludeoxyglucose uptake in head and neck squamous cell carcinomas sufficient for dose painting. *Acta Oncologica*, **2015**, 54, 1416-22 | 3.2 | 12 |
| 176 | Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer. *Advances in Radiation Oncology*, **2017**, 2, 259-269 | 3.3 | 12 |
| 175 | Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: a competing risks analysis. *British Journal of Cancer*, **2001**, 85, 1113-8 | 8.7 | 12 |
| 174 | Time factor for tonsillar carcinoma. *International Journal of Radiation Oncology Biology Physics*, **1995**, 33, 755-8 | 4 | 12 |
| 173 | Clinical Radiobiology and Normal-Tissue Morbidity after Breast Cancer Treatment. *Advances in Radiation Biology*, **1994**, 25-51 | | 12 |
| 172 | Continuous or split-course combined external and intracavitary radiotherapy of locally advanced carcinoma of the uterine cervix. *Acta Oncologica*, **1994**, 33, 547-55 | 3.2 | 12 |
| 171 | Can we optimize chemo-radiation and surgery in locally advanced stage III non-small cell lung cancer based on evidence from randomized clinical trials? A hypothesis-generating study. *Radiotherapy and Oncology*, **2009**, 93, 389-95 | 5.3 | 11 |
| 170 | Dose- and time-dependent changes in gene expression in human glioma cells after low radiation doses. *Radiation Research*, **2007**, 168, 199-208 | 3.1 | 11 |
| 169 | A user's guide to evidence-based oncology. *European Journal of Cancer, Supplement*, **2003**, 1, 77-91 | 1.6 | 11 |
| 168 | Radiotherapy for bone metastases. *Clinical Oncology*, **2001**, 13, 88-90 | 2.8 | 11 |
| 167 | In vitro radiosensitivity of tumour cells and fibroblasts derived from head and neck carcinomas: mutual relationship and correlation with clinical data. *British Journal of Cancer*, **1999**, 79, 1074-84 | 8.7 | 11 |
| 166 | Prophylactic cranial irradiation in limited stage small cell lung cancer: survival benefit in patients with favourable characteristics. *European Journal of Cancer*, **1996**, 32A, 772-8 | 7.5 | 11 |

| | | | |
|---|---|---|---|
| 165 | Histological grade, DNA ploidy and mean nuclear volume as prognostic factors in prostatic cancer. *Apmis*, **1993**, 101, 614-20 | 3.4 | 11 |
| 164 | Isotherm mapping in hyperthermia using subtraction X-ray computed tomography. *Radiotherapy and Oncology*, **1984**, 2, 255-60 | 5.3 | 11 |
| 163 | Late, Persistent, Substantial, Treatment-Related Symptoms After Radiation Therapy (LAPERS): A New Method for Longitudinal Analysis of Late Morbidity-Applied in the EMBRACE Study. *International Journal of Radiation Oncology Biology Physics*, **2020**, 106, 300-309 | 4 | 11 |
| 162 | Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma. *BMC Cancer*, **2018**, 18, 1026 | 4.8 | 11 |
| 161 | Genotyping of high-risk anal human papillomavirus (HPV): ion torrent-next generation sequencing vs. linear array. *Virology Journal*, **2017**, 14, 112 | 6.1 | 10 |
| 160 | Intratumor genetic heterogeneity in squamous cell carcinoma of the oral cavity. *Head and Neck*, **2019**, 41, 2514-2524 | 4.2 | 10 |
| 159 | Pathophysiological mechanisms underlying phenotypic differences in pulmonary radioresponse. *Scientific Reports*, **2016**, 6, 36579 | 4.9 | 10 |
| 158 | Comparison of radiation-induced normal lung tissue density changes for patients from multiple institutions receiving conventional or hypofractionated treatments. *International Journal of Radiation Oncology Biology Physics*, **2014**, 89, 626-32 | 4 | 10 |
| 157 | Methodologies for localizing loco-regional hypopharyngeal carcinoma recurrences in relation to FDG-PET positive and clinical radiation therapy target volumes. *Acta Oncologica*, **2010**, 49, 984-90 | 3.2 | 10 |
| 156 | Evidence based radiation oncology. *Radiotherapy and Oncology*, **1998**, 46, 1-3 | 5.3 | 10 |
| 155 | Early lesion-specific (18)F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer. *Radiotherapy and Oncology*, **2016**, 118, 460-4 | 5.3 | 9 |
| 154 | Immunohistochemical and molecular imaging biomarker signature for the prediction of failure site after chemoradiation for head and neck squamous cell carcinoma. *Acta Oncologica*, **2017**, 56, 1562-1570 | 3.2 | 9 |
| 153 | Dose-response relationships for late radiation effects in the head and neck: regarding the analysis of the RTOG 8313 trial, Fu et al. IJROBP 32:577-588; 1995. *International Journal of Radiation Oncology Biology Physics*, **1996**, 34, 523-5 | 4 | 9 |
| 152 | Prediction of radiotherapy response using SF2: why it may work after all. *Radiotherapy and Oncology*, **1994**, 31, 85-6 | 5.3 | 9 |
| 151 | Phase III trial of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) versus cisplatin, etoposide, bleomycin and prednisone (CisEBP) for the treatment of advanced non-Hodgkin's lymphoma of high grade malignancy. The Danish Lymphoma Study Group. *Acta Oncologica*, **1990**, 29, 995-9 | 3.2 | 9 |
| 150 | Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas **1998**, 32, 536 | | 9 |
| 149 | A failure-type specific risk prediction tool for selection of head-and-neck cancer patients for experimental treatments. *Oral Oncology*, **2017**, 74, 77-82 | 4.4 | 8 |
| 148 | Proton beam therapy delivered using pencil beam scanning vs. passive scattering/uniform scanning for localized prostate cancer: Comparative toxicity analysis of PCG 001-09. *Clinical and Translational Radiation Oncology*, **2019**, 19, 80-86 | 4.6 | 8 |

| | | | |
|---|---|---|---|
| 147 | Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection. *Lung Cancer*, **2018**, 123, 87-90 | 5.9 | 8 |
| 146 | Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study. *Journal of Neuro-Oncology*, **2018**, 140, 341-349 | 4.8 | 8 |
| 145 | A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients. *Oral Oncology*, **2018**, 81, 52-60 | 4.4 | 8 |
| 144 | Delay in diagnosis in breast cancer. *Lancet, The*, **1999**, 353, 2155-6 | 40 | 8 |
| 143 | Time evolution of the number of functional murine eccrine sweat glands after irradiation: a quantitative analysis of experimental data using a model of proliferative and functional organization. *International Journal of Radiation Biology*, **1995**, 67, 565-75 | 2.9 | 8 |
| 142 | Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation. *Cancer Chemotherapy and Pharmacology*, **2019**, 83, 1105-1112 | 3.5 | 7 |
| 141 | Changes in pulmonary function after definitive radiotherapy for NSCLC. *Radiotherapy and Oncology*, **2015**, 117, 23-8 | 5.3 | 7 |
| 140 | Harnessing data science to advance radiation oncology. *Molecular Oncology*, **2020**, 14, 1514-1528 | 7.9 | 7 |
| 139 | A Competing Risk Model of First Failure Site after Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2018**, 13, 559-567 | 8.9 | 7 |
| 138 | Implementation of and Early Outcomes From Anal Cancer Screening at a Community-Engaged Health Care Facility Providing Care to Nigerian Men Who Have Sex With Men. *Journal of Global Oncology*, **2019**, 5, 1-11 | 2.6 | 7 |
| 137 | Consensus Report From the Miami Liver Proton Therapy Conference. *Frontiers in Oncology*, **2019**, 9, 457 | 5.3 | 7 |
| 136 | Prescribing and evaluating target dose in dose-painting treatment plans. *Acta Oncologica*, **2014**, 53, 1251-62 | 3.2 | 7 |
| 135 | Re: five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. *Journal of the National Cancer Institute*, **1997**, 89, 1892-3 | 9.7 | 7 |
| 134 | Progression rate of radiation damage to the mouse kidney: a quantitative analysis of experimental data using a simple mathematical model of the nephron. *International Journal of Radiation Biology*, **1997**, 72, 461-73 | 2.9 | 7 |
| 133 | Influence of plasma glutathione levels on radiation mucositis. *International Journal of Radiation Oncology Biology Physics*, **2001**, 51, 460-4 | 4 | 7 |
| 132 | Quantitative assessment of radiation-induced lung changes by computerized optical densitometry of routine chest x-rays. *International Journal of Radiation Oncology Biology Physics*, **1996**, 34, 421-7 | 4 | 7 |
| 131 | A feasibility study of concomitant boost radiotherapy for patients with cancer of the supraglottic larynx. *Acta Oncologica*, **1993**, 32, 637-40 | 3.2 | 7 |
| 130 | Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement. *Radiotherapy and Oncology*, **2016**, 121, 440-446 | 5.3 | 7 |

| | | | |
|---|---|---|---|
| 129 | Does multiparametric imaging with F-FDG-PET/MRI capture spatial variation in immunohistochemical cancer biomarkers in head and neck squamous cell carcinoma?. *British Journal of Cancer*, **2020**, 123, 46-53 | 8.7 | 6 |
| 128 | Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer. *Lung Cancer*, **2017**, 114, 44-49 | 5.9 | 6 |
| 127 | Utilization of hypofractionated whole-breast radiation therapy in patients receiving chemotherapy: a National Cancer Database analysis. *Breast Cancer Research and Treatment*, **2017**, 165, 445-453 | 4.4 | 6 |
| 126 | Does routine clinical practice reproduce the outcome of large prospective trials? The analysis of institutional database on patients with limited-disease small-cell lung cancer. *Cancer Investigation*, **2014**, 32, 1-7 | 2.1 | 6 |
| 125 | A general framework for quantifying the effects of DNA repair inhibitors on radiation sensitivity as a function of dose. *Theoretical Biology and Medical Modelling*, **2007**, 4, 25 | 2.3 | 6 |
| 124 | Sequential or concurrent tamoxifen and radiotherapy: to see or not to see--that is the question!. *Journal of Clinical Oncology*, **2005**, 23, 6266-7; author reply 6267 | 2.2 | 6 |
| 123 | Are the results of the St Thomas' trial of post-mastectomy radiotherapy inconsistent with the predictions from the linear-quadratic model?. *British Journal of Radiology*, **1989**, 62, 633-5 | 3.4 | 6 |
| 122 | Dose Painting and Theragnostic Imaging: Towards the Prescription, Planning and Delivery of Biologically Targeted Dose Distributions in External Beam Radiation Oncology. *Cancer Treatment and Research*, **2008**, 40-61 | 3.5 | 6 |
| 121 | Reporting of Late Morbidity After Radiation Therapy in Large Prospective Studies: A Descriptive Review of the Current Status. *International Journal of Radiation Oncology Biology Physics*, **2019**, 105, 957-967 | 4 | 5 |
| 120 | Multiple HPV infections among men who have sex with men engaged in anal cancer screening in Abuja, Nigeria. *Papillomavirus Research (Amsterdam, Netherlands)*, **2020**, 10, 100200 | 4.6 | 5 |
| 119 | Biological optimization for mediastinal lymphoma radiotherapy - a preliminary study. *Acta Oncologica*, **2020**, 59, 879-887 | 3.2 | 5 |
| 118 | Radiation dose-painting with protons vs. photons for head-and-neck cancer. *Acta Oncologica*, **2020**, 59, 525-533 | 3.2 | 5 |
| 117 | Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients - initial observations. *PLoS ONE*, **2020**, 15, e0231884 | 3.7 | 5 |
| 116 | Modeling freedom from progression for standard-risk medulloblastoma: a mathematical tumor control model with multiple modes of failure. *International Journal of Radiation Oncology Biology Physics*, **2013**, 87, 422-9 | 4 | 5 |
| 115 | Late neurological complications after irradiation of malignant tumors of the testis. *Acta Oncologica*, **2007**, 46, 497-503 | 3.2 | 5 |
| 114 | Role of chance in familial aggregation of colorectal cancer. *British Journal of Cancer*, **2001**, 84, 1084-6 | 8.7 | 5 |
| 113 | Actual versus ideal treatment time in radiotherapy for head and neck cancer: catching up with the gaps. *International Journal of Radiation Oncology Biology Physics*, **1995**, 31, 687-8 | 4 | 5 |
| 112 | A mathematical model for cell killing by heat applied to a C3H mammary carcinoma in vivo. *International Journal of Radiation Biology*, **1993**, 64, 113-7 | 2.9 | 5 |

| | | | |
|---|---|---|---|
| 111 | A 100-year Nordic perspective on the dose-time problem in radiobiology. *Acta Oncologica*, **1995**, 34, 1031-40 | 3.2 | 5 |
| 110 | Impact of CT-based treatment planning on radiation therapy of carcinoma of the bladder. *Acta Radiologica Oncology*, **1984**, 23, 199-203 | | 5 |
| 109 | MO-D-M100J-01: Dose Painting With Intensity Modulated Proton Therapy and Intensity Modulated X-Ray Therapy: A Comparison. *Medical Physics*, **2007**, 34, 2522-2523 | 4.4 | 5 |
| 108 | Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Non-small-cell Lung Cancer Treated With Curative Intent. *Clinical Lung Cancer*, **2020**, 21, e130-e141 | 4.9 | 5 |
| 107 | Anal Microbial Patterns and Oncogenic Human Papillomavirus in a Pilot Study of Nigerian Men Who Have Sex with Men at Risk for or Living with HIV. *AIDS Research and Human Retroviruses*, **2019**, 35, 267-275 | 1.6 | 5 |
| 106 | Individualized estimates of overall survival in radiation therapy plan optimization - A concept study. *Medical Physics*, **2018**, 45, 5332-5342 | 4.4 | 5 |
| 105 | Patterns of Care and Survival in Stage III NSCLC Among Black and Latino Patients Compared With White Patients. *Clinical Lung Cancer*, **2019**, 20, 248-257.e4 | 4.9 | 4 |
| 104 | Prevalence of ATM Sequence Variants in Northern Plains American Indian Cancer Patients. *Frontiers in Oncology*, **2013**, 3, 318 | 5.3 | 4 |
| 103 | Does a local bystander effect necessitate a revision of TCP models that are based on observed clinical data?. *Acta Oncologica*, **2006**, 45, 406-11 | 3.2 | 4 |
| 102 | Is sensitization with nicotinamide and carbogen dependent on nicotinamide concentration at the time of irradiation?. *International Journal of Radiation Biology*, **2004**, 80, 499-506 | 2.9 | 4 |
| 101 | Lise Meitner and Niels Bohr--a historical note. *Acta Oncologica*, **2000**, 39, 1002-3 | 3.2 | 4 |
| 100 | Accelerated radiotherapy vs. chemoradiation in non-small cell lung cancer: quantifying the hazards. *Radiotherapy and Oncology*, **2001**, 58, 91-2 | 5.3 | 4 |
| 99 | Characterization and radiosensitivity of fibroblasts derived from squamous cell carcinomas of the head and neck, and the surrounding oral mucosa. *Acta Oncologica*, **1998**, 37, 697-700 | 3.2 | 4 |
| 98 | Repair capacity of mouse lung after total body irradiation alone or combined with cyclophosphamide. *Radiotherapy and Oncology*, **1996**, 40, 249-57 | 5.3 | 4 |
| 97 | Evaluation of bladder tumor volume and CT number during radiotherapy: a comment on the paper by Swank-Bordewijk and van Kleffens. *International Journal of Radiation Oncology Biology Physics*, **1985**, 11, 1228-9 | 4 | 4 |
| 96 | Lung Tumor Segmentation Using Electric Flow Lines for Graph Cuts. *Lecture Notes in Computer Science*, **2012**, 206-213 | 0.9 | 4 |
| 95 | Targeted Intraoperative Radiotherapy for Early Breast Cancer. *JAMA Oncology*, **2020**, 6, 1636 | 13.4 | 4 |
| 94 | Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax. *Blood Advances*, **2021**, 5, 711-724 | 7.8 | 4 |

| | | | |
|---|---|---|---|
| 93 | In Regard to Vaidya et´al. *International Journal of Radiation Oncology Biology Physics*, **2015**, 92, 954-955 | 4 | 3 |
| 92 | Hypofractionated radiation therapy for prostate cancer: more food for thought from recent trial. *Journal of Clinical Oncology*, **2014**, 32, 1852-3 | 2.2 | 3 |
| 91 | Increasing utilization of regional nodal irradiation in elderly node-positive women and declining emphasis on demographic factors. *Breast Cancer Research and Treatment*, **2017**, 165, 669-676 | 4.4 | 3 |
| 90 | Impact of a Contralateral Tumor Nodule on Survival in Non-Small-Cell Lung Cancer. *Journal of Thoracic Oncology*, **2015**, 10, 1608-15 | 8.9 | 3 |
| 89 | Radiation oncology advances: an introduction. *Cancer Treatment and Research*, **2008**, 139, 1-4 | 3.5 | 3 |
| 88 | Whole Brain Radiation Therapy With Hippocampal Avoidance and Simultaneously Integrated Brain Metastases Boost With Helical Tomotherapy: A Planning Study. *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, S674-S675 | 4 | 3 |
| 87 | 155. *International Journal of Radiation Oncology Biology Physics*, **2006**, 66, S87 | 4 | 3 |
| 86 | Chemotherapy and altered fractionation in head-and-neck cancer: in regard to Staar et al., IJROBP 2001;50:1161-1171. *International Journal of Radiation Oncology Biology Physics*, **2002**, 52, 1423; author reply 1423-4 | 4 | 3 |
| 85 | Treatment-related morbidity and hospital league tables: experience from a national audit of radiotherapy-induced morbidity in cervical carcinoma. *Clinical Oncology*, **2002**, 14, 40-2 | 2.8 | 3 |
| 84 | Introduction. *Seminars in Radiation Oncology*, **1994**, 4, 53-54 | 5.5 | 3 |
| 83 | Remodeling of trabecular bone at the proximal tibia after total knee replacement. A CT-scan study. *Engineering in Medicine*, **1986**, 15, 89-93 | | 3 |
| 82 | Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predictive Biomarkers and Clinical Outcomes. *Blood*, **2019**, 134, 3239-3239 | 2.2 | 3 |
| 81 | DNA Methylation in Prostate Tumor Tissue Is Associated with Gleason Score. *Genes*, **2020**, 12, | 4.2 | 3 |
| 80 | Primary Hypothyroidism in Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review. *International Journal of Radiation Oncology Biology Physics*, **2021**, | 4 | 3 |
| 79 | C5a Activates a Pro-Inflammatory Gene Expression Profile in Human Gaucher iPSC-Derived Macrophages. *International Journal of Molecular Sciences*, **2021**, 22, | 6.3 | 3 |
| 78 | Radiation Dose Escalation for Early Prostate Cancer: Reigniting the FLAME?. *Journal of Clinical Oncology*, **2021**, 39, 3085-3086 | 2.2 | 3 |
| 77 | Downstream Effect of a Proton Treatment Center on an Academic Medical Center. *International Journal of Radiation Oncology Biology Physics*, **2019**, 104, 756-764 | 4 | 2 |
| 76 | Inverse radiotherapy planning based on bioeffect modelling for locally advanced left-sided breast cancer. *Radiotherapy and Oncology*, **2019**, 136, 9-14 | 5.3 | 2 |

| | | | |
|---|---|---|---|
| 75 | Trends in utilization of hypofractionated whole breast irradiation (HF-WBI) in triple negative breast cancer (TNBC): a national cancer database (NCDB) analysis. *Breast Cancer Research and Treatment*, **2019**, 175, 473-478 | 4.4 | 2 |
| 74 | In Regard to Thomson et al. *International Journal of Radiation Oncology Biology Physics*, **2020**, 107, 853-854 | 4 | 2 |
| 73 | In Response to Dr. Williams. *International Journal of Radiation Oncology Biology Physics*, **2011**, 80, 639-640 | 4 | 2 |
| 72 | A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer: in regard to Arcangeli C, et al. (Int J Radiat Oncol Biol Phys 2010;78:11-18). *International Journal of Radiation Oncology Biology Physics*, **2011**, 80, 316; author reply 316-7 | 4 | 2 |
| 71 | 11 Design of clinical trials in radiation oncology: saving lives, not grays **2007**, 196-211 | | 2 |
| 70 | Dosimetric Evaluation of Helical IMRT, Traditional IMRT and 3-D Conformal Radiation for Inoperable Non-Small Cell Lung Cancer. *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, S632-S633 | 4 | 2 |
| 69 | Single Institution Experience Treating 100 Vestibular Schwannomas With Fractionated Stereotactic Radiation Therapy or Stereotactic Radiosurgery. *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, S121 | 4 | 2 |
| 68 | 2387. *International Journal of Radiation Oncology Biology Physics*, **2006**, 66, S425 | 4 | 2 |
| 67 | Pre-treatment haemoglobin concentration in accelerated and conventional radiotherapy for non-small cell lung carcinoma. *Clinical Oncology*, **2004**, 16, 58-62 | 2.8 | 2 |
| 66 | Predictors of hormone response for patients with ER-unknown breast tumours. *British Journal of Cancer*, **1989**, 59, 421-5 | 8.7 | 2 |
| 65 | Total Body Irradiation in Haematopoietic Stem Cell Transplantation for Paediatric Acute Lymphoblastic Leukaemia: Review of the Literature and Future Directions.. *Frontiers in Pediatrics*, **2021**, 9, 774348 | 3.4 | 2 |
| 64 | Postoperative Treatment of Locally Advanced Head and Neck Cancers **2005**, 197-210 | | 2 |
| 63 | Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients Is Associated With Underlying Non-Inflamed Tumor Profile. *Frontiers in Immunology*, **2021**, 12, 596646 | 8.4 | 2 |
| 62 | Pediatric Normal Tissue Effects in the Clinic (PENTEC): An International Collaboration to Assess Normal Tissue Radiation Dose-Volume-Response Relationships for Children With Cancer. *International Journal of Radiation Oncology Biology Physics*, **2021**, | 4 | 2 |
| 61 | Adherence to Guideline-Concordant Care and Its Effect on Survival in Black Patients with Head and Neck Cancers: A SEER-Medicare Analysis. *Oncologist*, **2021**, 26, 579-587 | 5.7 | 2 |
| 60 | Intratumor heterogeneity is biomarker specific and challenges the association with heterogeneity in multimodal functional imaging in head and neck squamous cell carcinoma. *European Journal of Radiology*, **2021**, 139, 109668 | 4.7 | 2 |
| 59 | Retrospective estimation of heart and lung doses in pediatric patients treated with spinal irradiation. *Radiotherapy and Oncology*, **2018**, 128, 209-213 | 5.3 | 2 |
| 58 | Effect of reduction mammoplasty on acute radiation side effects and use of lumpectomy cavity boosts. *Practical Radiation Oncology*, **2017**, 7, e299-e308 | 2.8 | 1 |

| | | | |
|---|---|---|---|
| 57 | Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia. *Journal of Clinical Medicine*, **2020**, 9, | 5.1 | 1 |
| 56 | In response to Dr. Pe□gar□ano. *International Journal of Radiation Oncology Biology Physics*, **2006**, 65, 1274-1275 | 4 | 1 |
| 55 | The Influence of Delay in Diagnosis of Breast Cancer upon Outlook. *Clinical Risk*, **2000**, 6, 4-6 | | 1 |
| 54 | Hyperthermia in cancer treatment. *Lancet, The*, **1995**, 345, 1635-1637 | 40 | 1 |
| 53 | 3-Methoxyazetidinium chloride. *Acta Crystallographica Section C: Crystal Structure Communications*, **1993**, 49, 932-934 | | 1 |
| 52 | Small cell anaplastic carcinoma of the lung. The Aarhus experience 1976-1981. *Acta Radiologica Oncology*, **1984**, 23, 153-8 | | 1 |
| 51 | Phase I clinical trial of DNA methyltransferase inhibitor decitabine and PARP inhibitor talazoparib combination therapy in relapsed/refractory acute myeloid leukemia.. *Clinical Cancer Research*, **2022**, | 12.9 | 1 |
| 50 | MO-D-M100J-08: Effect of a Biologically-Based Prescription Function in IMRT Dose Optimization. *Medical Physics*, **2007**, 34, 2524-2524 | 4.4 | 1 |
| 49 | Incorporating NTCP into Randomized Trials of Proton Versus Photon Therapy. *International Journal of Particle Therapy*, **2019**, 5, 24-32 | 1.5 | 1 |
| 48 | Repeatability of FDG PET/CT metrics assessed in free breathing and deep inspiration breath hold in lung cancer patients. *American Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 8, 127-136 | 2.2 | 1 |
| 47 | Proton vs photon radiation therapy for glioblastoma: Maximizing information from trial.. *Neuro-Oncology*, **2022**, | 1 | 1 |
| 46 | Fractionation Effects in Clinical Practice **2010**, 40-54 | | 1 |
| 45 | Radiobiological Aspects of Brachytherapy in the Era of 3-Dimensional Imaging **2011**, 131-142 | | 1 |
| 44 | In Reply to Berk and Alfonso. *International Journal of Radiation Oncology Biology Physics*, **2020**, 108, 834-835 | 4 | 1 |
| 43 | Persistence of Late Substantial Patient-Reported Symptoms (LAPERS) After Radiochemotherapy Including Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: A Report From the EMBRACE Study. *International Journal of Radiation Oncology Biology Physics*, **2021**, 109, 161-173 | 4 | 1 |
| 42 | Outcome-based multiobjective optimization of lymphoma radiation therapy plans. *British Journal of Radiology*, **2021**, 94, 20210303 | 3.4 | 1 |
| 41 | In Regard to Vaidya et al. *International Journal of Radiation Oncology Biology Physics*, **2015**, 92, 958-959 | 4 | 0 |
| 40 | Satisfaction with high-resolution anoscopy for anal cancer screening among men who have sex with men: a cross-sectional survey in Abuja, Nigeria. *BMC Cancer*, **2020**, 20, 98 | 4.8 | 0 |

| | | | |
|---|---|---|---|
| 39 | Patient reported outcomes following proton pencil beam scanning vs. passive scatter/uniform scanning for localized prostate cancer: Secondary analysis of PCG 001-09. *Clinical and Translational Radiation Oncology*, **2020**, 22, 50-54 | 4.6 | 0 |
| 38 | Aspartate Beta-Hydroxylase (ASPH) As a Novel Therapeutic Target in Acute Myeloid Leukemia. *Blood*, **2018**, 132, 5273-5273 | 2.2 | 0 |
| 37 | Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415. *PLoS ONE*, **2021**, 16, e0249123 | 3.7 | 0 |
| 36 | Metabolic heterogeneous zone assessed by FDG-PET is predictive of postablation mortality in patients with ventricular tachycardia. *Journal of Cardiovascular Electrophysiology*, **2021**, 32, 2238-2245 | 2.7 | 0 |
| 35 | Aspartate β-Hydroxylase (ASPH) Expression in Acute Myeloid Leukemia: A Potential Novel Therapeutic Target.. *Frontiers in Oncology*, **2021**, 11, 783744 | 5.3 | 0 |
| 34 | In Reply to Tommasino et´al. *International Journal of Radiation Oncology Biology Physics*, **2019**, 105, 677-678 | 4 | |
| 33 | On the relation between improved loco-regional control and disease-free survival in head-and-neck cancer. *Acta Oncologica*, **2019**, 58, 390-392 | 3.2 | |
| 32 | In reply to Yamazaki et al. *International Journal of Radiation Oncology Biology Physics*, **2015**, 91, 245-6 | 4 | |
| 31 | Equieffective dose and bioeffect modeling--in reply to Dr. Fowler. *Radiotherapy and Oncology*, **2013**, 108, 355 | 5.3 | |
| 30 | In reply to Arcangeli et al. *International Journal of Radiation Oncology Biology Physics*, **2013**, 85, 898-9 | 4 | |
| 29 | In reply to Boon et al. *International Journal of Radiation Oncology Biology Physics*, **2015**, 91, 456-7 | 4 | |
| 28 | Literature-based analysis of preoperative chemoradiotherapy in oesophageal cancer: In response to Srinivas et al.. *Radiotherapy and Oncology*, **2007**, 82, 107-108 | 5.3 | |
| 27 | Dose and fractionation regimens for breast cancer Authors' reply. *Lancet Oncology, The*, **2006**, 7, 619-620 | 21.7 | |
| 26 | REPLY TO LETTER TO THE EDITOR, REGARDING OUR PAPER INTERNATIONAL CONSENSUS ON PALLIATIVE RADIOTHERAPY ENDPOINTS FOR FUTURE CLINICAL TRIALS IN BONE METASTASES *Radiotherapy and Oncology*, **2003**, 67, 252 | 5.3 | |
| 25 | Dose escalation, treatment protraction, and the steepness of the dose-response curve for squamous cell carcinoma of the head and neck. *Radiotherapy and Oncology*, **1995**, 34, 82-83 | 5.3 | |
| 24 | Simulation of an HDR "Boost" with Stereotactic Proton versus Photon Therapy in Prostate Cancer: A Dosimetric Feasibility Study. *International Journal of Particle Therapy*, **2021**, 7, 11-23 | 1.5 | |
| 23 | Incidence of rib fractures after stereotactic body radiotherapy for peripheral lung lesions: clinical experience and dose response estimation. *Journal of Radiosurgery and SBRT*, **2011**, 1, 155-161 | 0.4 | |
| 22 | Radiation-Induced Toxicity Risks in Photon Versus Proton Therapy for Synchronous Bilateral Breast Cancer.. *International Journal of Particle Therapy*, **2022**, 8, 1-13 | 1.5 | |

| | | |
|---|---|---|
| 21 | MO-E-T-6E-02: Dose-Volume Modeling & Clinical Radiotherapy: The Art of Systematic Oversimplification. *Medical Physics*, **2005**, 32, 2072-2072 | 4.4 |
| 20 | TH-E-M100J-05: Early Assessment of Radiotherapy Efficacy with FLT-PET Imaging. *Medical Physics*, **2007**, 34, 2650-2650 | 4.4 |
| 19 | MO-D-BRA-01: Hypofractionated RT: Biological Basis and Clinical Application in the Prostate and Lung. *Medical Physics*, **2007**, 34, 2524-2525 | 4.4 |
| 18 | WE-D-AUD A-03: Control Theory to Manage Spatial and Temporal Physiologic Changes. *Medical Physics*, **2008**, 35, 2943-2943 | 4.4 |
| 17 | SU-DD-A1-04: Impact of Prescription Dose Gradient Discretization On Dose Painting. *Medical Physics*, **2008**, 35, 2631-2631 | 4.4 |
| 16 | SU-FF-T-519: Potential for Increased Pneumonitis Risk with IMRT as Compared to 3D-CRT for Patients Receiving Adjuvant Chemotherapy: A Radiobiological Modeling Study. *Medical Physics*, **2009**, 36, 2643-2643 | 4.4 |
| 15 | TH-D-304A-06: Comparison of Cu-ATSM and FMISO Uptake to Variations in Oxygen Tension. *Medical Physics*, **2009**, 36, 2817-2817 | 4.4 |
| 14 | SU-FF-T-499: Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC): Limits and Recommendations for Use in Treatment Planning. *Medical Physics*, **2009**, 36, 2638-2638 | 4.4 |
| 13 | MO-D-204B-01: Characterizing Uncertainties in Hypoxia Imaging-Based Dose Painting Prescriptions. *Medical Physics*, **2010**, 37, 3341-3341 | 4.4 |
| 12 | Evidence-Based Head and Neck Oncology: Principles and Pitfalls **2011**, 317-325 | |
| 11 | TU-A-BRC-04: Quantifying the Predictive Power of Multiparametric PET Imaging in a Prospective Veterinary Dose Escalation Trial through Voxel Regression. *Medical Physics*, **2011**, 38, 3742-3742 | 4.4 |
| 10 | MO-A-BRCD-01: Unsettled Issues in the Radiobiology of Emergent Technology: Hypofractionation and PET-Guided Treatment Planning. *Medical Physics*, **2012**, 39, 3858 | 4.4 |
| 9 | SU-E-T-167: QA of Dose-Painting Plans: Risk of Overdosage in the High-Dose Regions?. *Medical Physics*, **2013**, 40, 242-242 | 4.4 |
| 8 | TU-C-WAB-01: Accuracy Requirements and Uncertainty Considerations in Radiation Therapy. *Medical Physics*, **2013**, 40, 433-433 | 4.4 |
| 7 | TH-A-WAB-11: A Novel Method to Determine Alpha/beta for Irradiated Normal Lung Tissue Using Computed Tomography Scans. *Medical Physics*, **2013**, 40, 522-522 | 4.4 |
| 6 | Brief Report: Herpes Simplex Virus Type-2 Shedding and Genital Ulcers During Early HIV in Zimbabwean Women. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2021**, 87, 789-793 | 3.1 |
| 5 | Outcomes of a Community-based Breast Cancer Screening Program in Baltimore City. *Journal of Health Care for the Poor and Underserved*, **2018**, 29, 898-913 | 1.4 |
| 4 | Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients Initial observations **2020**, 15, e0231884 | |

3 Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients Initial observations **2020**, 15, e0231884

2 Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients Initial observations **2020**, 15, e0231884

1 Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients Initial observations **2020**, 15, e0231884